Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model | JAMA Oncology | JAMA Network

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model | JAMA Oncology | JAMA Network

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast CancerA Life-Table Model

Nora Pashayan, MD, PhD¹; Steve Morris, PhD¹; Fiona J. Gilbert, MBChB, FRCR²; et alPaul D. P. Pharoah, MBBS, PhD³

Author Affiliations Article Information

JAMA Oncol. Published online July 5, 2018. doi:10.1001/jamaoncol.2018.1901